cyrilzakka/clinical-trials huggingface dataset:
Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers

Computed tomography (CT) images, used for radiotherapy planning, are often caught out in lung target volumes delineation because of their inability to differentiate between neoplasia, inflammation and atelectasia. Positron Emission Tomography (PET) is a new functional imaging modality and is currently used in the diagnosis and the staging of lung cancers. The aim of this study is to evaluate the impact of 4D 18F-FDG-PET-CT on radiotherapy planning for lung cancers.

Many PET studies have been interested in lung radiotherapy volumes definition, however lacking any standardisation. Effectively, the use of PET images is difficult because of the poor image quality resulting from noise and partial volume effects induced blurring. Moreover, due to the long duration of PET acquisitions, respiratory motions are inevitable and result in artifacts in the PET images affecting the volumes and contrast of the tumour: tumours may appear larger while their activity can be lower. To overcome these limitations, we propose to use a 4D PET-CT, ie a PET-CT acquisition system synchronized with respiration in order to compare CT-simulation target volumes and PET target volumes after application of different approaches for partial volume effect correction, respiratory motion correction and automatic segmentation method of functional volumes. For this purpose, patients with a non small cell lung cancer and having to be treated with radiotherapy or radio-chemotherapy underwent CT-simulation and 4D PET-CT in radiotherapy treatment position. The target volumes and the dosimetries obtained with both modalities were compared.

Eligibility Criteria:
Inclusion Criteria:

* age ≥ 18 years old
* patients with unresectable non small cell lung cancer having to be treated with radiotherapy or radio-chemotherapy

Exclusion Criteria:

* neo-adjuvant treatment
* patient treated previously with thoracic radiation
* patient unable to support 4D PET-CT
* pregnant or breast-feeding woman
The Feasibility and Safety of a Three-Port Laparoscopic Cholecystectomy Using a 2-mm Mini-Instrument

The aim of this study was to show that this technique is feasible, safe and easily reproducible and to evaluate the selection criteria for a three-port laparoscopic cholecystectomy using a 2-mm mini-port.

Since the first four-port laparoscopic cholecystectomy (LC) was reported in 1987, various surgical options for LC have been developed. Recently, single port LC (SPLC) has been increasingly performed to minimize tissue trauma, improve cosmesis and decrease postoperative pain for patients. Some surgeons suggest that the four- or three-port LC using mini-ports could be as safe, effective, economical and cosmetic as SPLC. For this reason, the investigators started M-LC for patients with benign gallbladder disease in April 2010.

Prospectively collected data from 133 patients who underwent LC for benign gallbladder disease between April 2010 and April 2011 were retrospectively reviewed.

The patient's selection for M-LC was determined by surgeon's judgment based on 'laparoscopic surgical view' after inserting the laparoscope in the operating room.

Eligibility Criteria:
Inclusion Criteria:

* all patients required laparoscopic cholecystectomy for benign gallbladder diseases.

Exclusion Criteria:

* open cholecystectomy
Accuracy of CBCT Imaging and Intraoral Scanner in Dental Plaster Casts Digitization: A Validity and Reliability Study

The Objective of this study is to evaluate the accuracy of CBCT and intraoral scanner, in digitization of dental plaster casts, by comparing them to desktop optical scanner as a gold standard.

The Objective of this study is to evaluate the accuracy of CBCT and intraoral scanner, in digitization of dental plaster casts, by comparing them to desktop optical scanner as a gold standard.

Planmeca CBCT Modality, Haron 3DISC intraoral scanner will be used as index tests, and Medit T710 desktop optical scanner will be used as the gold standard.

STL files from test scanning modalities will be compared using the surface matching software (Geomagic control X). The surface matching software will automatically register the two compared STL files together using the best-fit alignment tool and will generate the 3D compare for the surface comparison between them.

Eligibility Criteria:
Inclusion Criteria:

* Adult dental casts with complete dentition and/or partially edentulous regions.
* Maxillary and mandible casts are both included.
* Intact casts without voids, cracks, or visible porosities

Exclusion Criteria:

* Casts of pediatric patients.
* Completely edentulous casts.
* Casts with hypodontia, supernumerary teeth or fractured teeth.
* Casts with retainers, metallic appliances, or partial dentures.
* Casts with voids, fractures, cracks or visible porosities.
Measures to Increase the Effectiveness of Fast Track Colorectal Clinics for Iron Deficiency Anaemia.

A retrospective cohort study was conducted from 2016-18 in a single busy district general hospital providing services to a population of 700,000 people.

In the study, patients with true IDA (low MCV and ferritin) were found to be more likely to have Colorectal cancer compared to any other type of anaemia which confirmed the latest guidelines for management of IDA. Compared to symptoms, only the presence of a mass on abdominal examination and rectal examination was found to be more likely associated with cancer.

Although there are strict and specific guidelines for referring patients with iron deficiency anaemia (IDA) to fast track colorectal cancer (FT CRC) clinics for further assessment and investigation, patients with other types of anaemia are still referred by primary care physicians in the UK. Investigators aim was to find out whether this practice is correct, or if it is causing an overburden on colorectal clinics and endoscopy services. Investigators also want to find out whether true/absolute IDA has a higher predictive value for diagnosing colorectal cancer (CRC) compared to other types of anaemia and specific bowel symptoms.

Investigator's hypothesis was that patients with IDA are more likely to have CRC compared to patients with no anaemia or non-IDA anaemia. By confirming this hypothesis, Investigators can identify high risk patients from the population who can then be preferentially subjected to investigations mandated by guidelines. This strategy can help to increase the diagnostic yield of FT CRC clinics.

A retrospective cohort study was conducted from 2016-18 in a single busy district general hospital providing services to a population of 700,000 people.

In the study, patients with true IDA (low MCV and ferritin) were found to be more likely to have CRC compared to any other type of anaemia which confirmed the latest guidelines for management of IDA. Compared to symptoms, only the presence of a mass on abdominal examination and rectal examination was found to be more likely associated with cancer.

Physicians should be able to stratify patients based on blood indices when referring them to FT CRC clinics. Diagnostic yield of these clinics can be increased if clinicians strictly adhere to fast track guidelines and confirm true IDA before referring patients to clinic.

Eligibility Criteria:
Inclusion Criteria:

- Patients with age more than 18 years Presenting to fast track colorectal clinic

1. With bowel symptoms
2. Presenting with anaemia
3. Rectal bleeding

Exclusion Criteria:

* Any patient presenting through routine colorectal clinics

  1. With bowel symptoms
  2. Presenting with anaemia
  3. Rectal bleeding Aged less than 18 years
Intravesical Thermochemotherapy With Mitomycin-c

To investigate effect of intravesical mitomycin-C(MMC) applied with bladder wall thermotherapy system on reccurrence and progression status of intermediate and high risk non muscle invasive bladder cancer

Before the application of TCT, complete transurethral bladder tumour resection (TURBT) was performed. RE-TURBT was conducted within 4 weeks for patients with initial T1 pathology. The first TCT instillation was applied at 1mo following the TURBT or the RE-TURBT.

Thermochemotherapy application and treatment schedule:

The bladder wall TCT (BWT) system (Elmedical Ltd, Hod-Hasharon, Israel) was used as a conductive heating modality. MMC (40 mg; MMC Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan) was mixed with 50 mL of 0.9% saline solution and applied using a disposable silicone 20Fr 3-way TCT catheter (UniThermia catheter; Elmedical Ltd). In each session, the bladder was irrigated with MMC solution at 42°C-45°C for 45 min via the BWT system. The treatment schedule consisted of an initial 6-week instillation, followed by control cystoscopy and urine cytology in the 3rd month and monthly instillations up to 1 yr. Urine cytology and cystoscopy were performed every three months. The samples were collected from the suspected areas during cystoscopy. At the end of the first year, control cystoscopy with random bladder biopsies was conducted. During the second year, routine controls were conducted every three months. Subsequently, follow-ups were performed every six months. In case of development of any complication in a patient, TCT was discontinued. Before each instillation of TCT, clear urine cultures were obtained from all patients. No prophylactic anticholinergic was administered prior to intravesical TCT. If TUR BT pathology was Ta or T1 during the follow-up, it was accepted as a recurrence. If it was CIS or T2, it was accepted as a progression. All adverse events observed during the study were recorded according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 \[9. All study protocols were approved by the local ethical committee at our institution. An informed consent was obtained from all patients.

Eligibility Criteria:
Inclusion Criteria:

* newly diagnosed or followed as recurrent intermediate-risk non muscle invasive non muscle invasive bladder cancer according to the criteria of European Association of Urology.
* newly diagnosed or followed as recurrent high-risk non muscle invasive non muscle invasive bladder cancer according to the criteria of European Association of Urology.
* pathology of urothelial carcinoma

Exclusion Criteria:

* Low bladder capacity (\<150ml)
* increased post voiding residual urine (\>150ml)
* untreatable or uncontrollable urinary tract infection
* history of urethral stricture
* presence of bladder diverticula larger than 1 cm
* pathology other than urothelial carcinoma
* WHO (World Health Organization) performance status \> 2
* upper urinary tract urothelial carcinoma diagnosis
The Immediate Effects of Post Isometric Relaxation Techniques

Aim: The aim of this study is to investigate the immediate effects of Post Isometric Relaxation (PIR) Technique on pain threshold, pain severity and joint range of motion of the cervical region in healthcare workers with neck pain.

Method: A total of 30 male and female participants aged 20-45 were randomly divided into two groups (Post Isometric Relaxation (PIR) Technique and Control Group). PIR group participants were under a single session of PIR application with 10 repetitions to m.supraspinatus, the upper part of the m.trapeze and m.levator scapula in addition to classical Swedish massage for neck and upper thoraric region. Control group participants received only classical Swedish massage to the cervical and upper thoracic region. Pain severity (Visual Analog Scale), Pain threshold (digital algometer), range of servical motion (goniometer) were measured at baseline and immediately after the single-session PIR Techniques.

Neck pain is the second most common musculoskeletal problem in the world after low back pain in terms of disability and health expenditures. Occupational groups with the highest incidence of neck pain include those working in a hospital environment, office workers, and manual workers.

Post Isometric Relaxation Technique (PIR) is a Muscle Energy Technique (MET) and is used by physiotherapists to relax muscles, reduce pain and increase range of motion. The PIR Technique provides its neurological effects through autogenic inhibition, which results in relaxation in the agonist muscle by inhibiting contraction with the stimuli sent by the group Ib fibers originating from the Golgi tendon organ of the agonist muscle to the medulla spinalis during static stretching.

The aim of our study is to investigate the instantaneous effect of PIR Technique on pain threshold, pain intensity and joint range of motion (neck flexion, extension, right and left rotation, right and left lateral flexion) in hospital workers with neck pain.

This experimental study, which was planned as randomized and single-blind, was planned to be carried out with a total of 30 volunteer participants, male and female, working in a private hospital in Istanbul between 7 October 2022 and 10 December 2022.

Eligibility Criteria:
Inclusion Criteria:

* be a hospital worker
* complaining of neck pain for at least 3 months
* pain intensity at rest is 4 out of 10 according to VAS assessment
* volunteer to participate in the study

Exclusion Criteria:

* Having neck pain after trauma to the neck in the last 6 months
* presence of neurological signs; neck pain that has spread to the arm and fingers
* have had spinal surgery
* shoulder pathology
To Prevent Type I-II Myoma After TCRM Recurrence by Gonadotropin-releasing Hormone (GnRH )Analogues or Mifepristone

Transcervical resection of myoma(TCRM) has a good therapeutic effect while the probability of complete resection of type I and II fibroids is only 55% per procedure on average and a significant number of patients have fibroid remained.At present, there is no standardized treatment option for reducing the remaining submucous fibroids volume and preventing its recurrence after TCRM.The present prospective,multicentre,randomised controlled clinical trial will enrol women after TCRM and treat them with mifepristone(10mg)or GnRHa(3.60mg)for 3 to 6 months,investigating the effective and cost-effective treatment options after fibroids with TCRM，thus to provide evidence and effectual regiments for reducing remaining fibroids volume and preventing its recurrence.


Eligibility Criteria:
Inclusion Criteria:

1. Age more than 18 years and less than 45 years old, no childbirth requirements in the next 3 years;
2. Type I and II submucosal fibroids diagnosed by ultrasound, and the diameter of them are greater than 3cm;
3. Type I or II submucosal fibroids confirmed by TCRM and no degeneration confirmed pathologically;
4. A MRI test will be done to evaluate the residual submucosal fibroids and calculate the residual fibroid volume after 1 month of surgery;
5. Patients would not had used drugs such as mifepristone and GnRHa 3 months before surgery;
6. Participate in this trial and sign the informed consent form voluntarily .

Exclusion Criteria:

1. Combined with congenital uterine malformations such as double uterus, unicornuate uterus, etc;
2. Have fertility requirements within 3 years after surgery;
3. Estrogen-dependent diseases such as adenomyosis and endometriosis;
4. Drugs such as mifepristone or GnRHa have been used before surgery;
5. Mifepristone or GnRHa drug treatment is contraindicated or cannot tolerate TCRM surgery.
Sciatic Block in Contralateral Limb Phantom and Residual Limb Pain

Participants with chronic, refractory phantom limb pain (PLP) or residual limb pain (RLP) for more than 6 months will be enrolled in this clinical trial. Aim: Define the attributable pain relief and functional improvement in participants with PLP/RLP after contralateral limb sciatic nerve block. Also, contribute to the basic science understanding of the crossed-withdraw reflex by demonstrating a known animal model phenomenon in human participants. Hypothesis: Contralateral limb sciatic nerve anesthetic block with 2% lidocaine provides immediate clinically meaningful pain reduction, defined as the proportion of patients with at least 50% improvement in numeric rating scale (NRS) pain score in PLP/RLP when compared to sham.


Eligibility Criteria:
Inclusion Criteria:

* 1. Age greater than 18 years of age at day of enrollment
* 2. Lower extremity amputation performed more than 12 months before study enrollment
* 3. PLP/RLP in affected amputated limb \> 4 on numeric rating scale 26 (NRS26)
* 4. Pain duration of more than 6 months despite a trial of conservative therapies for at least 2 months, including oral medications, topical medicines, physical therapy, and physical modalities (i.e., heat, cold, transcutaneous electrical nerve stimulation, phonophoresis)
* 5. Willingness to undergo image guided diagnostic nerve block

Exclusion Criteria:

* 1. Refusal / inability to participate or provide consent
* 2. Contraindications to diagnostic nerve block
* 3. Non-neurogenic source of PLP/RLP
* 4. Current opioid use \> 50 morphine milligram equivalents per day
* 5. Any interventional pain treatment in the residual limb within the last 30 days
* 6. Severe uncontrolled medical condition (i.e., hypertensive crisis, decompensated hypothyroidism)
* 7. Use of investigational pain drug within past 30 days or other concurrent clinical trial enrollment
Effect of Applying Ujjayi Pranayama on Cortisol in Lupus Patients

stress vulnerability is very common in lupus patients, specifically women, hence the rates of depression , insomnia, easy fatigue perception, anxiety are high in those women. pranayama is a yogic intervention that may treat the above problems

lupus patients, specifically 40 women, will divided to group number 1 and group number 2. the women in every group will be 20 women. Group number 1 will receive home-based ujjayi pranayama for six weeks (fifteen minutes in the morning and 15 min in the evening, this training will be online supervised). The group number 2 will not receive Ujjayi pranayama, so it serves as control lupus group

Eligibility Criteria:
Inclusion Criteria:

* 40 lupus women

Exclusion Criteria:

* lupus co-morbidities
* illiteracy
Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658

This trial is conducted in Europe. The aim of this trial is to obtain the PTPN11 mutation status and investigate the impact of the PTPN11 mutation status on the effect of somatropin (Norditropin®) by use of data obtained in the GHNOO-1658 trial.


Eligibility Criteria:
Inclusion Criteria:

* Participation in the GHNOO-1658 trial
* Subject has completed genetic testing of PTPN11 mutation
Use of Breath Stacking Technique on Regional Ventilation in Box Chest in Women With Morbid Obesity

Objectives: To evaluate the effects of the technique of Breath Stacking (BS) in the distribution of ventilation in the chest in women with morbid obesity. Methods: Randomized clinical trial, blinded, and controlled with 32 women (BMI ≥ 40kg/m2), separated into two groups: control (GC) with n = 16 and 41.94 ± 9.38 years and group Breath Stacking (GBS) , n = 16 and 40.38 ± 10.16 years. Optoelectronic plethysmography (POE) was used to assess lung ventilation. For the BS technique was used to mask the expiratory branch occluded and Wright spirometer. GBS held three techniques with an interval of three minutes. The GC used the same circuit without the occlusion of the expiratory branch. Results: GBS was found to be higher in the contribution of tidal volume (VT) into the chest circumference (p = 0.04) and decrease in abdominal compartment (p = 0.03), whereas the CG showed no difference in distribution. Spirometric variables: FEV1 (%), FVC (%), FEV1/FVC (%), VC and CI showed no difference before and after the technical BS and GBS in the GC. Conclusions: The technique BS altered the distribution pattern of regional ventilation, resulting in greater contribution in lung volume in the lower rib cage, corresponding to activity of the diaphragm, with redistribution of volume between compartments.


Eligibility Criteria:
Inclusion Criteria:

* Women aged 19-60 years
* BMI ≥ 40 kg/m2

Exclusion Criteria:

* Women with chronic lung disease
* Smokers
* Neuromuscular disease
* Disability in performing the procedures
Heat-not-burn Tobacco Product to Aid in Switching From Combustible to Noncombustible Nicotine (IQOS)

A novel heat-not-burn tobacco product (IQOS) will be provided to smokers, compared against a (cigarette) smoking as usual period in counter-balanced order in a cross-over design. This study will examine the short-term effects of IQOS, switching from combustible to noncombustible nicotine and withdrawal-related symptoms over a two week-long "practice" period, relative to smoking as usual.

The current within-subjects crossover study aims to directly compare initial efficacy of IQOS vs (cigarette) smoking as usual on switching from tobacco cigarettes during two-week "practice" periods in smokers.

Study interventions include IQOS, a commercially available, over the counter product. The IQOS is a commercially available tobacco product that consists of a holder which contains a rechargeable battery and an electronically heated metal blade.

All procedures will take place in the Prevention and Early Detection Center (PEDC) at the UPMC Hillman Cancer Center. Participants will be assessed daily via remote CO assessment and online questionnaire throughout the entire study (WK1-WK5). At the end of a one-week baseline of normal smoking (WK1), participants will be randomized to either: 1) begin a two-week period of attempting to completely switch to exclusive IQOS use (IQOS First); or 2) continue to smoke as usual (IQOS Last; WK2-WK3), followed by a second two-week period during which they will smoke as usual or attempt to switch to IQOS (opposite of the first period; WK4-WK5).

Eligibility Criteria:
Inclusion Criteria:

* Male or female, ages 21-77
* Current smoker with ≥5 cigarettes per day for ≥1 year history of smoking
* Screening CO ≥8 ppm
* Not currently interested in quitting smoking
* Willing to briefly switch from combustible to noncombustible nicotine
* Have reliable daily access to a smartphone or tablet compatible with the iCO Smokerlyzer app:

  * Android 8 or higher, iOS 8 or higher
  * Bluetooth-enabled device

Exclusion Criteria:

* Current use of smoking cessation medications such as varenicline or bupropion
* Major chronic medical problems, including cardiovascular disease, diabetes
* Pregnancy (a urine pregnancy test will be administered at screening for all women of child bearing potential).